2 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
| 1 | 26303225 | PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. | 2015 Oct | 1 |
| 2 | 23718933 | Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis. | 2013 Sep | 1 |